Johnson & Johnson

Latest Headlines

Latest Headlines

Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund

The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe.

Don't expect a generics-style smackdown from Remicade biosims, J&J CEO says

Johnson & Johnson is feeling the pain from Remicade biosimilars outside the U.S. But it's got a message for worried investors who fear this is just the beginning of a massive downward spiral: Biosimilars are not generics.

Investor urges J&J to spin out poor-performing device, consumer businesses

It's not a new argument, but it's back on the table again now in a big way. Activist investor Artisan Partners is working to convince other investors to back splitting conglomerate Johnson & Johnson into three separate businesses.

J&J to fork over $120M to settle thousands of vaginal mesh suits

Johnson & Johnson is shelling out more than $120 million to settle thousands of lawsuits from women who claim that the company's vaginal mesh inserts caused them pain and injury, months after other companies facing related suits such as Boston Scientific and C.R. Bard announced similar settlement agreements.

UPDATED: Big investor pushes 'underperforming' J&J to step up or split up

Should Johnson & Johnson join the Big Pharma split-up club? One of its major shareholders thinks so, and it's pressing activist investors to join the cause.

No obvious China baby bump for J&J as one-child policy ends

Johnson & Johnson executives had only a few words on China in the fourth quarter earnings call and even less on Asia outside of the predictable hit from foreign currency swings, with analyst attention focused on M&A moves.

J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations

After disclosing a major restructuring of its medical device business last week, Johnson & Johnson tried to refocus on the future of that group on its annual earnings call. It emphasized doing more deals to acquire platforms for growth, as well as funneling more resources to high revenue growth device groups.

J&J's new launches deliver, but overall sales fall short on hep C, strong dollar

Johnson & Johnson's hep C sales have been nosediving, and the fourth quarter provided more of the same on that front. But in the quarter, a strong dollar took a toll on the company's top line, too, dragging sales below analyst estimates.

J&J loses bid to dismiss false advertising lawsuit over baby products

Johnson & Johnson was hoping to put a marketing case around its Bedtime Products for babies to rest, but a federal judge isn't having it.

J&J's DePuy comes under fire for all-metal hip manufacturing in U.K.

Johnson & Johnson's DePuy unit has faced plenty of pushback the past few years over its all-metal hip implants, with patients suing the company for alleged design defects causing pain and injury. Now the company is in the hot seat again, and this time, it's for manufacturing problems in the U.K. linked to the devices.